v3.26.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
Three months ended March 31,
20262025
Collaborative arrangement revenue$1,533 $1,481 
Less:
OCU4001,299 1,835 
OCU410 and OCU410ST2,625 1,190 
NeoCart12 (3)
COVAXIN
Inhaled mucosal vaccine platform30 197 
OCU200198 249 
Unallocated costs:
Research and development personnel costs5,509 4,020 
Facilities and other support costs833 966 
Other 742 1,070 
Total research and development11,255 9,529 
General and administrative8,117 6,453 
Total operating expenses19,372 15,982 
Loss from operations(17,839)(14,501)
Other income (expense):
Interest income132 343 
Interest expense(1,320)(1,257)
Other (expense) income, net(150)65 
Total other (expense) income(1,338)(849)
Segment and consolidated net loss(19,177)(15,350)